Do you want to experience what it’s really like to be a scientist?Continue reading
GammaTile® Therapy is FDA-cleared as a treatment for patients with newly diagnosed malignant intracranial neoplasms and patients with recurrent intracranial neoplasms, including brain metastases, glioblastomas, and meningiomas.Continue reading
The University of Arizona Health Sciences is one of five sites that will be tracking the burden, distribution and impact of post COVID-19 conditions.
TUCSON, Ariz., Dec. 09, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing precision medicine through its innovative transcriptome-wide profiling and advanced medicinal chemistry technology, today announced it will host its next HTG Therapeutics key opinion leader (KOL) webinar: “The Role of RNA Profiling in Drug Discovery and Analysis”, on Tuesday, December 13, 2022 at 11:00 am Eastern Standard Time.Continue reading
-JSR Lifesciences invested $1.5M toward the preferred series A capital raise, October 2022.
-The dosing of the P1A Healthy Human Volunteer Study with ALT-100 mAb is nearing completion, with no reported SAEs to date. Study to conclude by Q2 2023.Continue reading
Technology developed at TGen described in a new study.
PHOENIX, Ariz. — December 5, 2022 — With less than one microliter of blood plasma or serum, researchers can now use a customizable lab platform called PepSeq to observe how the tiny sample interacts with hundreds of thousands of protein building blocks.Continue reading
TapRoot Interventions & Solutions, Inc (TapRoot) is partnering with psychiatric and behavioral health provider group Peace of Mind Consultants (POMC) in Arizona to provide Ella® to their patients and business partners. Ella is a digital careplan platform that provides interventions to prevent, decrease, and de-escalate dementia-related and mental illness-related behavioral symptoms known to occur in Long Term Care communities. POMC will use Ella to garner key insights from caregiver feedback in order to tailor patient-specific treatment plans and determine appropriate use of medications. The value of the partnership is a provider service model coupled with a caregiver platform to assess, evaluate, and provide outcome measures to improve overall resident care.Continue reading
TUCSON, Ariz., Dec. 1, 2022 — Critical Path Institute (C-Path) and Ultragenyx Pharmaceutical, Inc., (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today announced a data sharing agreement to incorporate rare disease patient data into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®).Continue reading
ADP provides an experienced and practical approach for guiding life science clients through the R&D tax credit process. Their group of specialized professionals provide the peace of mind that comes with having a highly detailed study outlining qualified research activities and expenses.Continue reading